key: cord-0837031-qwzksqyr
authors: Kochhar, Sonali; Dubé, Eve; Graham, Janice; Jee, Youngmee; Memish, Ziad A.; Menning, Lisa; Nohynek, Hanna; Salmon, Daniel; Top, Karina A.; MacDonald, Noni E.
title: COVID-19 Vaccine Safety Questions and Answers for Healthcare Providers (CONSIDER)
date: 2021-03-22
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.03.060
sha: b4147cfd7a7a23f89358ca8a16a3d6522f7b7a80
doc_id: 837031
cord_uid: qwzksqyr

nan

Sonali Kochhar, MD 1 , Eve Dubé, PhD 2 , Janice Graham, PhD 3 , Youngmee Jee MD, PhD 4 Due to the need for widespread uptake of COVID-19 vaccines, their safety is of utmost importance. The accelerated pace of vaccine development has raised concerns among some healthcare providers and the public regarding whether critical steps in vaccine development are being skipped, especially steps in assessment of vaccine safety, to compress the usual decades long vaccine development process into 12-15 months. Vaccine hesitancy is being fueled by concerns regarding the COVID-19 pandemic response of vaccine manufacturers, regulatory agencies and their governments. There is growing suspicion regarding vaccines in some population groups. [2] [3] [4] [5] [6] As for all new vaccines, there is the possibility that rare serious adverse reactions will not be identified in clinical trials and only found once a larger number of people are vaccinated. 4 Additionally, when vaccinating a large number of people, some of them will have adverse health outcomes shortly after vaccination by chance alone. 4 8 This is key as information alone is not synonymous with knowledge, with the latter implying the "skillful interpretation and application of that information". 9

The answers can also be used to help national and subnational health authorities in training and educating healthcare workers (including those providing immunization services) and in updating National Immunization Technical Advisory Groups (NITAGs) and Regional Immunization 

the submitted work; neither she nor her unit received such private funds/grants; KT received personal fees from Pfizer and grants from GSK outside the submitted work; DS received grants from Walgreens and personal fees from Merck and Janssen, outside the submitted work Role of funding source -There was no funding received for this work.

Next-generation vaccine platforms for COVID-19

Planning for a COVID-19 Vaccination Program

Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly

Planning for COVID-19 vaccines safety surveillance

Vaccine safety concerns: Should we be changing the way we support immunization?

Safety of Vaccines Used for Routine Immunization in the United States: An Update. US Agency for Healthcare Research and Quality Effective Health Care Program

When Will We Have a Vaccine?" -Understanding Questions and Answers about Covid-19 Vaccination

Supporting informed decision-making about vaccination: an analysis of two official websites

Highlighting consensus among medical scientists increases public support for vaccines: evidence from a randomized experiment